Teacher Retirement System of Texas Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Teacher Retirement System of Texas boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 32.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 38,932 shares of the biopharmaceutical company's stock after purchasing an additional 9,554 shares during the quarter. Teacher Retirement System of Texas' holdings in Regeneron Pharmaceuticals were worth $27,732,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in REGN. Amundi lifted its position in Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock valued at $1,138,074,000 after purchasing an additional 487,489 shares during the last quarter. Proficio Capital Partners LLC grew its position in Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock worth $156,284,000 after acquiring an additional 219,162 shares in the last quarter. Worldquant Millennium Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $127,489,000. Thrivent Financial for Lutherans raised its position in Regeneron Pharmaceuticals by 1,272.7% during the fourth quarter. Thrivent Financial for Lutherans now owns 125,194 shares of the biopharmaceutical company's stock valued at $89,179,000 after purchasing an additional 116,074 shares during the period. Finally, KBC Group NV lifted its stake in shares of Regeneron Pharmaceuticals by 296.7% in the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company's stock valued at $97,338,000 after purchasing an additional 102,198 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Remove Ads

Regeneron Pharmaceuticals Stock Up 0.9 %

NASDAQ REGN traded up $6.00 during trading on Wednesday, hitting $640.14. The company's stock had a trading volume of 1,251,798 shares, compared to its average volume of 639,898. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $630.62 and a fifty-two week high of $1,211.20. The company has a market cap of $69.98 billion, a PE ratio of 16.72, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The business's 50 day simple moving average is $687.18 and its 200-day simple moving average is $806.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. During the same period last year, the business earned $11.86 EPS. Regeneron Pharmaceuticals's revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's payout ratio is 2.30%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on REGN shares. UBS Group downgraded Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their target price for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Bank of America reiterated an "underperform" rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Sanford C. Bernstein lowered their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th. Citigroup cut their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Finally, Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and boosted their target price for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.